{"address1": "1 North Waukegan Road", "city": "North Chicago", "state": "IL", "zip": "60064-6400", "country": "United States", "phone": "847 932 7900", "website": "https://www.abbvie.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Beh\u00e7et's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; California Institute for Biomedical Research (Calibr), and BigHat Biosciences, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Richard A. Gonzalez", "age": 69, "title": "Chairman & CEO", "yearBorn": 1954, "fiscalYear": 2022, "totalPay": {"raw": 6948244, "fmt": "6.95M", "longFmt": "6,948,244"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 43528872, "fmt": "43.53M", "longFmt": "43,528,872"}}, {"maxAge": 1, "name": "Mr. Robert A. Michael", "age": 53, "title": "President & COO", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 3998042, "fmt": "4M", "longFmt": "3,998,042"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 13150419, "fmt": "13.15M", "longFmt": "13,150,419"}}, {"maxAge": 1, "name": "Mr. Scott T. Reents", "age": 55, "title": "Executive VP & CFO", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 2972736, "fmt": "2.97M", "longFmt": "2,972,736"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 5172329, "fmt": "5.17M", "longFmt": "5,172,329"}}, {"maxAge": 1, "name": "Dr. Azita  Saleki-Gerhardt Ph.D.", "age": 60, "title": "Executive VP & COO", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 2576755, "fmt": "2.58M", "longFmt": "2,576,755"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 28534760, "fmt": "28.53M", "longFmt": "28,534,760"}}, {"maxAge": 1, "name": "Mr. Jeffrey Ryan Stewart", "age": 54, "title": "Executive VP & Chief Commercial Officer", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 2983231, "fmt": "2.98M", "longFmt": "2,983,231"}, "exercisedValue": {"raw": 2777988, "fmt": "2.78M", "longFmt": "2,777,988"}, "unexercisedValue": {"raw": 10864175, "fmt": "10.86M", "longFmt": "10,864,175"}}, {"maxAge": 1, "name": "Dr. Thomas J. Hudson M.D.", "age": 61, "title": "Senior VP & Chief Scientific Officer of Global Research", "yearBorn": 1962, "fiscalYear": 2022, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Elizabeth  Shea", "title": "Senior Vice President of Investor Relations", "fiscalYear": 2022, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Sanjay  Narayan", "title": "SVP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal", "fiscalYear": 2022, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Timothy J. Richmond", "age": 57, "title": "Executive VP & Chief Human Resources Officer", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 1121841, "fmt": "1.12M", "longFmt": "1,121,841"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Wulff-Erik  von Borcke", "title": "Senior VP of AbbVie & President of Oncology", "fiscalYear": 2022, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 7, "boardRisk": 5, "compensationRisk": 6, "shareHolderRightsRisk": 9, "overallRisk": 8, "governanceEpochDate": 1706745600, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 174.79, "open": 175.07, "dayLow": 173.05, "dayHigh": 175.4, "regularMarketPreviousClose": 174.79, "regularMarketOpen": 175.07, "regularMarketDayLow": 173.05, "regularMarketDayHigh": 175.4, "dividendRate": 6.2, "dividendYield": 0.0356, "exDividendDate": 1705276800, "payoutRatio": 2.1764998, "fiveYearAvgDividendYield": 4.47, "beta": 0.542, "trailingPE": 64.0, "forwardPE": 14.304027, "volume": 3502661, "regularMarketVolume": 3502661, "averageVolume": 5392026, "averageVolume10days": 5611710, "averageDailyVolume10Day": 5611710, "bid": 173.0, "ask": 174.08, "bidSize": 800, "askSize": 1200, "marketCap": 308598571008, "fiftyTwoWeekLow": 130.96, "fiftyTwoWeekHigh": 175.91, "priceToSalesTrailing12Months": 5.6813316, "fiftyDayAverage": 158.893, "twoHundredDayAverage": 147.8654, "trailingAnnualDividendRate": 5.99, "trailingAnnualDividendYield": 0.034269694, "currency": "USD", "fromCurrency": null, "toCurrency": null, "lastMarket": null, "coinMarketCapLink": null, "algorithm": null, "tradeable": false, "enterpriseValue": 355271770112, "profitMargins": 0.08953, "floatShares": 1761653239, "sharesOutstanding": 1765539968, "sharesShort": 13718240, "sharesShortPriorMonth": 12084497, "sharesShortPreviousMonthDate": 1703808000, "dateShortInterest": 1706659200, "sharesPercentSharesOut": 0.0078, "heldPercentInsiders": 0.00135, "heldPercentInstitutions": 0.72029, "shortRatio": 2.57, "shortPercentOfFloat": 0.0078, "impliedSharesOutstanding": 1772739968, "category": null, "bookValue": 6.85, "priceToBook": 25.41314, "fundFamily": null, "legalType": null, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "earningsQuarterlyGrowth": -0.668, "netIncomeToCommon": 4863000064, "trailingEps": 2.72, "forwardEps": 12.17, "pegRatio": 4.77, "lastSplitFactor": null, "enterpriseToRevenue": 6.541, "enterpriseToEbitda": 13.532, "52WeekChange": 0.132375, "SandP52WeekChange": 0.21495235, "lastDividendValue": 1.55, "lastDividendDate": 1705017600, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "ABBV", "underlyingSymbol": "ABBV", "shortName": "AbbVie Inc.", "longName": "AbbVie Inc.", "firstTradeDateEpochUtc": 1357137000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "73238d42-cdcc-3f92-8141-dd675addae10", "messageBoardId": "finmb_141885706", "gmtOffSetMilliseconds": -18000000, "currentPrice": 174.08, "targetHighPrice": 205.0, "targetLowPrice": 135.0, "targetMeanPrice": 176.5, "targetMedianPrice": 177.5, "recommendationMean": 2.2, "recommendationKey": "buy", "numberOfAnalystOpinions": 24, "totalCash": 13290000384, "totalCashPerShare": 7.527, "ebitda": 26254331904, "totalDebt": 61182001152, "totalRevenue": 54317998080, "debtToEquity": 504.427, "revenuePerShare": 30.636, "returnOnEquity": 0.33132, "earningsGrowth": -0.668, "revenueGrowth": -0.054, "grossMargins": 0.69207, "ebitdaMargins": 0.48334, "operatingMargins": 0.31459, "financialCurrency": "USD"}